
Biobot Analytics converts wastewater into actionable population-level public health intelligence for governments, healthcare providers, and researchers. It combines molecular assays and laboratory analysis with AI-driven data modeling to quantify pathogens and chemical biomarkers in sewage. The company operates a B2B public-health data platform that delivers trend reports and dashboards to public health agencies, universities, and pharmaceutical customers. Biobot's platform has been used to track disease spread and substance use trends and has been integrated into national surveillance initiatives to help anticipate hospitalizations and allocate resources.

Biobot Analytics converts wastewater into actionable population-level public health intelligence for governments, healthcare providers, and researchers. It combines molecular assays and laboratory analysis with AI-driven data modeling to quantify pathogens and chemical biomarkers in sewage. The company operates a B2B public-health data platform that delivers trend reports and dashboards to public health agencies, universities, and pharmaceutical customers. Biobot's platform has been used to track disease spread and substance use trends and has been integrated into national surveillance initiatives to help anticipate hospitalizations and allocate resources.
Founded: 2017
Headquarters / Area: Boston/Cambridge area
Core offering: Wastewater intelligence platform for population-level public health surveillance
Customers: Governments, public health agencies, universities, pharmaceutical/enterprise customers
Total funding (reported): USD 41,398,737
Wastewater epidemiology / population-level public health surveillance
2017
Biotechnology
Most recent round listed on Crunchbase as Series A closed on June 6, 2025
Crunchbase records indicate 10 funding rounds and ~29 investors
Press release announced a new round led by Valor Equity Partners with participation from Atreides Management and Hyperplane; Vivek Pattipati (Valor) joining board
“Includes strategic and venture investors such as Valor Equity Partners, Atreides Management, Hyperplane, Plum Alley Investments, Anne Wojcicki, and Tom Knight”